Skip to content

A study on the efficacy and brain mechanism of treating negative symptoms of schizophrenia based on intermittent theta burst stimulation

A study on the efficacy and brain mechanism of treating negative symptoms of schizophrenia based on intermittent theta burst stimulation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097853
Enrollment
Unknown
Registered
2025-02-26
Start date
2024-03-05
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Study group 2:iTBS given at the left DLPFC stimulation site
Study group 1:iTBS was administered with the left cerebellar vermis as the target of stimulation.
Normal control group:Recruitment of 150 mentally and physically healthy normal individuals aged 18-40 years with no mental illness in their family. And their cranial magnetic resonance was collected

Sponsors

Shandong Mental Health Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Meet DSM-5 diagnostic criteria for schizophrenia; 2. Age 18-40 years old, male or female, right-handed; 3. At present, negative symptoms are the main symptoms, and the factor score of the negative symptom scale of PANSS is >=20 points, and at least one of the negative symptoms of the PANSS is >=4 points; 4. Stable psychiatric symptoms, no obvious positive symptoms, PANSS positive symptom scale < 20 points, and each individual score needs to be <4 points; 5. Antipsychotic medication treatment was stable for at least 4 weeks prior to enrollment, and the medication regimen remained unchanged throughout the study. Normal control group: age 18-40 years; No family members with mental illness.

Exclusion criteria

Exclusion criteria: 1. Have severe cerebral organic diseases, such as epilepsy; 2. Accompanied by serious physical diseases, such as cardiovascular diseases, liver and kidney diseases, etc.; 3. History of substance abuse and psychoactive substance use; 4. Those who are mentally retarded and mentally retarded; 5. Those with contraindications to TMS treatment; 6. Pregnant or lactating women; 7. Received transcranial magnetic stimulation therapy or MECT therapy in the past six months; 8. Those with contraindications to magnetic resonance scanning.

Design outcomes

Primary

MeasureTime frame
Positive and Negative Syndrome Scale, PANSS;

Secondary

MeasureTime frame
Repeatable Battery for the assessment of neuropsyc-hological status,RBANS;Hamilton Anxiety Scale,HAMA;Hamilton Depression Scale,HAMD;

Countries

China

Contacts

Public ContactShan Xiaoxiao

Shandong Mental Health Center

shanxiaoxiao22@126.com+86 156 6666 4337

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 28, 2026